ISG15 as a novel tumor biomarker for drug sensitivity

被引:60
作者
Desai, Shyamal D. [1 ]
Wood, Laurence M. [1 ]
Tsai, Yu-Chen [1 ]
Hsieh, Tao-Shih [2 ]
Marks, Jeffrey R. [3 ]
Scott, Georgia L. [3 ]
Giovanella, Beppino C. [4 ]
Liu, Leroy F. [1 ]
机构
[1] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, Piscataway, NJ 08854 USA
[2] Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA
[3] Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA
[4] Stehlin Fdn Canc Res, Houston, TX USA
关键词
D O I
10.1158/1535-7163.MCT-07-2345
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Tumor cells are known to exhibit highly varied sensitivity to camptothecins (CPT; e.g., irinotecan and topotecan). However, the factors that determine CPT sensitivity/resistance are largely unknown. Recent studies have shown that the ubiquitin-like protein, IFN-stimulated gene 15 (ISG15), which is highly elevated in many human cancers and tumor cell lines, antagonizes the ubiquitin/proteasome pathway. In the present study, we show that ISG15 is a determinant for CPT sensitivity/resistance possibly through its effect on proteasome-mediated repair of topoisomerase I (TOP1)-DNA covalent complexes. First, short hairpin RNA-mediated knockdown of either ISG15 or UbcH8 (major E2 for ISG15) in breast cancer ZR-75-1 cells decreased CPT sensitivity, suggesting that ISG15 overexpression in tumors could be a factor affecting intrinsic CPT sensitivity in tumor cells. Second, the level of ISG15 was found to be significantly reduced in several tumor cells selected for resistance to CPT, suggesting that altered ISG15 regulation could be a significant determinant for acquired CPT resistance. Parallel to reduced CPT sensitivity, short hairpin RNA-mediated knockdown of either ISG15 or UbcH8 in ZR-75-1 cells resulted in increased proteasomal degradation of CPT-induced TOP1-DNA covalent complexes. Taken together, these results suggest that ISG15, which interferes with proteasome-mediated repair of TOP1-DNA covalent complexes, is a potential tumor biomarker for CPT sensitivity.
引用
收藏
页码:1430 / 1439
页数:10
相关论文
共 41 条
[1]   Stage-associated overexpression of the ubiquitin-like protein, ISG15, in bladder cancer [J].
Andersen, J. B. ;
Aaboe, M. ;
Borden, E. C. ;
Goloubeva, O. G. ;
Hassel, B. A. ;
Orntoft, T. F. .
BRITISH JOURNAL OF CANCER, 2006, 94 (10) :1465-1471
[2]   The interferon regulated ubiquitin-like protein, ISG15, in tumorigenesis: Friend or foe? [J].
Andersen, J. B. ;
Hassel, B. A. .
CYTOKINE & GROWTH FACTOR REVIEWS, 2006, 17 (06) :411-421
[3]  
BEIDLER DR, 1995, MOL PHARMACOL, V47, P907
[4]   Mechanisms of cellular resistance to camptothecins [J].
Beretta, G. L. ;
Perego, P. ;
Zunino, F. .
CURRENT MEDICINAL CHEMISTRY, 2006, 13 (27) :3291-3305
[5]   Autocatalytic subunit processing couples active site formation in the 20S proteasome to completion of assembly [J].
Chen, P ;
Hochstrasser, M .
CELL, 1996, 86 (06) :961-972
[6]   Retinoic acid-induced protein ISGylation is dependent on interferon signal transduction [J].
Dao, Chinh T. ;
Luo, Jiann-Kae ;
Zhang, Dong-Er .
BLOOD CELLS MOLECULES AND DISEASES, 2006, 36 (03) :406-413
[7]   ISG15: A ubiquitin-like enigma [J].
Dao, CT ;
Zhang, DE .
FRONTIERS IN BIOSCIENCE-LANDMARK, 2005, 10 :2701-2722
[8]   Herc5, an interferon-induced HECT E3 enzyme, is required for conjugation of ISG15 in human cells [J].
Dastur, A ;
Beaudenon, S ;
Kelley, M ;
Krug, RM ;
Huibregtse, JM .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (07) :4334-4338
[9]  
Davis PL, 1998, ANTICANCER RES, V18, P2919
[10]  
DCunha J, 1996, J IMMUNOL, V157, P4100